Editorial
Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer
Abstract
A little over three decades ago, early trials with intravesical instillations of chemotherapeutic agents were found disappointing (1). Later, putting forward the hypothesis that the mechanism of recurrence was the implantation of cancer cells after tumour resection, research demonstrated the role of intravesical mitomycin C (MMC) in decreasing the risks of recurrence (2).
